SOUTH SAN FRANCISCO, CA, Sep. 18, 2009 (Marketwire) --
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/18/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) today is scheduled to provide a corporate update on the company's research and development pipeline highlighting its focus to advancing novel, internally-discovered drug candidates that are directed to the biology of muscle function and contractility.
"As we will elaborate today, Cytokinetics has leveraged our expertise focused to cytoskeletal biology and the pharmacology of muscle function to construct a preclinical and clinical pipeline of novel compounds directed to activating or inhibiting muscle contractility," stated Robert I. Blum, President and Chief Executive Officer of Cytokinetics. "We believe that our productive research and development activities have yielded a pipeline of multiple compounds that are specifically engineered to potentially address key liabilities of existing drugs. In particular, we believe each of our clinical programs focused to cardiac and skeletal muscle may have the potential to define new paradigms for the treatment of severe diseases that are increasingly amongst the major contributors to the mortality, morbidities and excessive costs associated with aging demographics."
Mr. Blum will be accompanied by Sharon Barbari, EVP Finance and Chief Financial Officer, David Morgans, Ph.D., EVP Preclinical Research and Development, Andrew Wolff, M.D., FACC, SVP Clinical Research and Development and Chief Medical Officer and Fady Malik, M.D., Ph.D., FACC, Vice President Biology and Therapeutics to discuss the status of the clinical and nonclinical programs. In addition, the Cytokinetics team will be joined by thought leaders who have been invited to provide additional commentary as follows: Barry Greenberg, M.D., Professor of Medicine at the University of California San Diego and Director of the Advanced Heart Failure Treatment Program at the University of California Medical Center in San Diego; Jeffrey Rothstein, M.D., Ph.D., Professor of Neurology and Neuroscience at Johns Hopkins University; and Roger A. Fielding, Ph.D.
